The first randomized trial to examine if older adults with multiple sclerosis can discontinue disease-modifying therapy after years of being relapse-free failed to deliver a definitive conclusion.
The novel anti-CD20 monoclonal antibody ublituximab showed greater improvement vs terifulnomide in stabilizing disease progression in relapsing multiple sclerosis in two phase 3 trials.
The investigational evobrutinib, an Bruton s tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.
Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.